# Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?

> **NCT02022358** · PHASE2 · TERMINATED · sponsor: **University College, London** · enrollment: 34 (actual)

## Conditions studied

- Osteosarcoma
- Spindle Cell Sarcoma of Bone

## Interventions

- **DRUG:** Glucarpidase
- **DRUG:** Methotrexate
- **DRUG:** Folinic Acid

## Key facts

- **NCT ID:** NCT02022358
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Recruitment almost complete, has been slow and challenging
- **Last updated:** 2015-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02022358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02022358, "Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02022358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*